Information  X 
Enter a valid email address

Futura Medical PLC (FUM)

  Print      Mail a friend       Annual reports

Tuesday 05 March, 2019

Futura Medical PLC

Notice of Preliminary Results

RNS Number : 8147R
Futura Medical PLC
05 March 2019


Notice of Preliminary Results

05 March 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, will announce its preliminary results for the year ended 31 December 2018 on Wednesday 10 April 2019.

James Barder, Chief Executive Officer, and Angela Hildreth, Finance Director/Chief Operating Officer, will host a presentation for analysts at 10am BST on the day of the results at the office of N+1 Singer at 1 Bartholomew Lane, London EC2N 2AX.

A copy of the announcement will be made available on the Futura Medical website and following the results meeting a webcast of the presentation to analysts will also be made available within the Investor Centre section of the site.

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [email protected]
Tel: +44 (0) 1483 685 670

Nominated Adviser and Broker:
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate Finance)

Mia Gardner/ Tom Salvesen (Corporate Broking)
Tel: +44 (0) 20 7496 3000


For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: [email protected]

Tel: +44 (0) 203 950 9144


Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.


Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t